Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Operating Expenses (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Operating Expenses for 3 consecutive years, with $66.0 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 17.88% to $66.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $248.2 million through Dec 2025, up 11.87% year-over-year, with the annual reading at $248.2 million for FY2025, 11.87% up from the prior year.
  • Operating Expenses hit $66.0 million in Q4 2025 for NewAmsterdam Pharma, up from $55.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $71.9 million in Q1 2025 to a low of $44.2 million in Q2 2023.
  • Historically, Operating Expenses has averaged $55.6 million across 3 years, with a median of $54.8 million in 2024.
  • Biggest YoY gain for Operating Expenses was 26.41% in 2025; the steepest drop was 0.13% in 2025.
  • Year by year, Operating Expenses stood at $51.9 million in 2023, then rose by 7.95% to $56.0 million in 2024, then rose by 17.88% to $66.0 million in 2025.
  • Business Quant data shows Operating Expenses for NAMS at $66.0 million in Q4 2025, $55.5 million in Q3 2025, and $54.8 million in Q2 2025.